250214-44-9

Basic information

• Product Name: FESOTERODINE
• Synonyms: FESOTERODINE;2-Methylpropanoic acid 2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester
• CAS NO: 250214-44-9
• Molecular Formula: C26H37NO3
• Molecular Weight: 411.582
• Mol File: 250214-44-9.mol

Chemical Properties

• Boiling Point: 518.9 °C at 760 mmHg
• Flash Point: 267.6 °C
• Appearance: /
• Density: 1.043
• PKA: 14.27±0.10(Predicted)
• CAS DataBase Reference: FESOTERODINE(CAS DataBase Reference)
• NIST Chemistry Reference: FESOTERODINE(250214-44-9)
• EPA Substance Registry System: FESOTERODINE(250214-44-9)

Safety Data

• Hazardous Substances Data: 250214-44-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Fesoterodine is used as a therapeutic agent for the treatment of overactive bladder symptoms such as frequent urination, urgent urination, and urinary incontinence. Its application is aimed at providing relief from these symptoms by improving urinary control and reducing the frequency and urgency of urination.
Used in Urology:
Fesoterodine is used as a medication in urology to manage patients with overactive bladder conditions. It is particularly beneficial for those who experience a significant impact on their quality of life due to these symptoms. The use of fesoterodine in this context is to enhance bladder function and reduce the occurrence of incontinence episodes.
Common side effects associated with the use of fesoterodine may include dry mouth, constipation, and blurred vision. It is crucial for patients to consult with a healthcare professional to discuss the potential benefits and risks of using fesoterodine before initiating treatment. The medication is typically administered orally in the form of extended-release tablets and should be taken as directed by a medical professional.

Upstream product

• 79-30-1 isobutyryl chloride 
• 207679-81-0 (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)-phenol 
• 286930-03-8 fesoterodine fumarate 
• 1206695-46-6 2-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-hydroxy-methylphenyl isobutyrate mandelate 
• 214601-16-8 N,N-diisopropyl-3-(2-hydroxy-5-methyloxycarbonylphenyl)-3-phenylpropanamine 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 906532-26-1 3-(N,N-diisopropylamino)-1-phenylpropan-1-ol 
• 214601-16-8 (R)-(-)-3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzoic acid methyl ester 
• 1294517-15-9 methyl (R)-(-)-3-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxy-benzoate 2,3-dibenzoyl-D-tartaric acid salt 
• 140-10-3 (E)-3-phenylacrylic acid 
• 156755-35-0 methyl 4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]benzoate 
• 950773-38-3 R-(-)-[3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl]diisopropylamine 
• 106-41-2 4-bromo-phenol 
• 156755-23-6 6-bromo-4-phenyl-3,4-dihydro-2H-chromen-2-one 

Downstream Products

• 286930-03-8 2-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate fumarate 
• 200801-70-3 RS-N,N-diisopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES

3,3-diphenylpropylamines of general formula (I), particularly Fesoterodine, as well as their enantiomers, solvates and salts, can be produced by treating a compound of formula (II) with a chiral alcohol to yield the diastereomeric esters of formula (IV) and (IV′), which can be further transformed into a compound of formula (I), or an enantiomer, solvate or salt thereof, wherein R1 is C1-C8 alkyl; and R2 and R3, independently of one another, represent H or C1-C6 alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound.

PROCESS FOR THE PREPARATION OF 2-(3-N,N-DIISOPROPYLAMINO-1-PHENYLPROPYL)-4-HYDROXYMETHYL-PHENOL AND ITS DERIVATIVES

The invention concerns a process for the preparation of 2-(3-N,N- diisopropylamino-l-phenylpropyl)-4-hydroxymethyl-phenol and its derivatives, particularly the corresponding (R) 4-trityloxymethyl derivative, useful as intermediate form in the synthesis of Fesoterodine and its salts, in particular for the preparation of Fesoterodine fumarate salt.

PROCESS FOR THE PREPARATION OF FESOTERODINE OR ITS SALTS

The present invention relates to a process for the preparation of fesoterodine or its salts.

PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES

The invention relates to a process for obtaining 3,3-diphenylpropylamines of general formula (I), particularly Fesoterodine, as well as their enantiomers, solvates and salts, comprising treating a compound of formula (II) with a chiral alcohol to yield the diastereomeric esters of formula (IV) and (IV'), which can be further transformed into a compound of formula (I), or an enantiomer, solvate or salt thereof, wherein R1 is C1-C8 alkyl; and R2 and R3, independently of one another, represent H or C1-C6 alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound.

PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST

The present invention relates to novel and improved processes for the preparation of (r)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenylisobutyrate represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.

A PROCESS FOR PREPARING FESOTERODINE

The present invention relates to an improved process for the preparation of Fesoterodine and pharmaceutically acceptable salts thereof. The present invention particularly relates to a process for the preparation of fesoterodine and pharmaceutically acceptable salts thereof which involves use and preparation of R(+) benzyl tolterodine and fumarate salt of R(+)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol.

"Process for the preparation of fesoterodine or a salt thereof"

A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities.

PROCESS FOR THE PREPARATION OF FESOTERODINE OR A SALT THEREOF

A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities.

PROCESSES FOR THE PREPARATION OF FESOTERODINE

The invention relates to improved process for the preparation of fesoterodine and its pharmaceutically acceptable salt, specifically fesoterodine fumarate of formula (1). The invention relates to solid state forms of a novel salt of fesoterodine and process for the preparation thereof. The invention also relates to highly pure fesoterodine fumarate substantially free of impurity X at RRT 1.37. The invention also provides solid particles of pure fesoterodine fumarate wherein 90 volume-percent of the particles (D90) have a size of higher than 200 microns.

SHORT SYNTHESIS OF TOLTERODINE, INTERMEDIATES AND METABOLITES

A process is described for the preparation of intermediates which can be used for preparation of agents for urinary incontinence therapy, specifically to 2-(3-(diisopropylamino)- 1-phenylpropyl)-4-(hydroxymethyl)phenol and its prodrugs.